Cited by 4,360SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesImmune responses and vaccinations

The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.

The trinity of COVID-19: immunity, inflammation and intervention

Open access

Tay, Matthew Zirui, Poh, Chek Meng, Rénia, Laurent, MacAry, Paul A., Ng, Lisa F. P.·2020·Nature Reviews Immunology

DOI 10.1038/s41577-020-0311-8PMC PMC7187672

Open this paper in CoChat — free account Open PDF

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic. Alongside investigations into the virology of SARS-CoV-2, understanding the fundamental physiological and immunological processes underlying the clinical manifestations of COVID-19 is vital for the identification and rational design of effective therapies. Here, we provide an overview of the pathophysiology of SARS-CoV-2 infection. We describe the interaction of SARS-CoV-2 with the immune system and the subsequent contribution of dysfunctional immune responses to disease progression. From nascent reports describing SARS-CoV-2, we make inferences on the basis of the parallel pathophysiological and immunological features of the other human coronaviruses targeting the lower respiratory tract - severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Finally, we highlight the implications of these approaches for potential therapeutic interventions that target viral infection and/or immunoregulation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41577-020-0311-8

Cites

139 of 139 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Gautret, P., Lagier, J., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Esteves-Vieira, V., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
Retracted
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Epidemiological and clinical characteristics of 99 cases of 2019 novel Coronavirus pneumonia in Wuhan, China: a descriptive study.
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-Infected pneumonia in Wuhan, China
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575

Show all 136 references

Research works printed but not linked: 3

Pipeline Review. APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease COVID-19 in China. Pipeline Review https://pipelinereview.com/index.php/2020022673884/Proteins-and-Peptides/APEIRONs-respiratory-drug-product-to-start-pilot-clinical-trial-to-treat-coronavirus-disease-COVID-19-in-China.html (2020).
Humanigen. Humanigen partners with CTI, a leading contract research organization, for planned phase III study for lenzilumab for coronavirus treatment. Humanigen https://www.humanigen.com/press/Humanigen-Partners-With-CTI%2C-A-Leading-Contract-Research-Organization%2C-For-Planned-Phase-III-Study-For-Lenzilumab-For-Coronavirus-Treatment (2020).
VIR. Press release details: Vir Biotechnology applying multiple platforms to address public health risk from Wuhan coronavirus. VIR https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-applying-multiple-platforms-address-public (2020).

Sorted by citations

Items 301–400 of 1,002

Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants
Catteau, L., Dauby, N., Montourcy, M., Bottieau, E., Hautekiet, J., Goetghebeur, E. J. T., van Ierssel, S. H., Duysburgh, E., Oyen, H. J. V., Wyndham-Thomas, C., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106144 · Cited by 120
Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2–Specific IgG
Schwarzkopf, S., Krawczyk, A., Knop, D., Klump, H., Heinold, A., Heinemann, F. M., Thümmler, L., Temme, C., Breyer, M., Witzke, O., et al. (2020) · Emerging infectious diseases · doi:10.3201/2701.203772 · Cited by 138
SARS-CoV-2-Induced ARDS Associates with MDSC Expansion, Lymphocyte Dysfunction, and Arginine Shortage
Reizine, F., Lesouhaitier, M., Grégoire, M., Pinceaux, K., Gacouin, A., Maamar, A., Painvin, B., Camus, C., Tulzo, Y. L., Tattevin, P., et al. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-020-00920-5 · Cited by 121
Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations
Bayram, N., Özsaygılı, C., Sav, H., Tekin, Y., Gündoğan, M., Pangal, E., Çiçek, A., & Özcan, İ. (2021) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-021-00845-5 · Cited by 120
Interleukin-6, CXCL10 and Infiltrating Macrophages in COVID-19-Related Cytokine Storm: Not One for All But All for One!
Coperchini, F., Chiovato, L., & Rotondi, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.668507 · Cited by 116
Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report
Buckland, M. S., Galloway, J. B., Fhogartaigh, C. N., Meredith, L. W., Provine, N. M., Bloor, S., Ogbe, A., Zelek, W. M., Smielewska, A., Yakovleva, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19761-2 · Cited by 119
Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates
He, L., Lin, X., Wang, Y., Abraham, C., Sou, C., Ngo, T., Zhang, Y., Wilson, I. A., & Zhu, J. (2021) · Science Advances · doi:10.1126/sciadv.abf1591 · Cited by 121
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
Ader, F., Peiffer‐Smadja, N., Poissy, J., Bouscambert‐Duchamp, M., Belhadi, D., Diallo, A., Delmas, C., Saillard, J., Dechanet, A., Mercier, N., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.05.020 · Cited by 118
Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies
Zhou, Y., Xie, Y., Tang, L., Pu, D., Zhu, Y., Liu, J., & Ma, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00733-x · Cited by 116
Vasculopathy in COVID-19
Flaumenhaft, R. C., Enjyoji, K., & Schmaier, A. A. (2022) · Blood · doi:10.1182/blood.2021012250 · Cited by 121
Dynamic blood single-cell immune responses in patients with COVID-19
Huang, L., Shi, Y., Gong, B., Jiang, L., Zhang, Z., Liu, X., Yang, J., He, Y., Jiang, Z., Zhong, L., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00526-2 · Cited by 116
Botanical drugs and supplements affecting the immune response in the time of COVID ‐19: Implications for research and clinical practice
Brendler, T., Al‐Harrasi, A., Bauer, R., Gafner, S., Hardy, M. L., Heinrich, M., Hosseinzadeh, H., Izzo, A. A., Michaelis, M., Nassiri‐Asl, M., et al. (2020) · Phytotherapy Research · doi:10.1002/ptr.7008 · Cited by 122
Role of Mitochondria in Viral Infections
Elesela, S., & Lukacs, N. W. (2021) · Life · doi:10.3390/life11030232 · Cited by 113
Immunoinformatic Analysis of SARS-CoV-2 Nucleocapsid Protein and Identification of COVID-19 Vaccine Targets
Oliveira, S. C., de Magalhães, M. T. Q., & Homan, E. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.587615 · Cited by 115
COVID‐19 and Treg/Th17 imbalance: Potential relationship to pregnancy outcomes
Muyayalo, K. P., Huang, D., Zhao, S., Xie, T., Mor, G., & Liao, A. (2020) · American Journal of Reproductive Immunology · doi:10.1111/aji.13304 · Cited by 120
Selenium and viral infection: are there lessons for COVID-19?
Bermano, G., Méplan, C., Mercer, D. K., & Hesketh, J. E. (2020) · British Journal Of Nutrition · doi:10.1017/s0007114520003128 · Cited by 118
Antiviral and Immunomodulatory Effects of Phytochemicals from Honey against COVID-19: Potential Mechanisms of Action and Future Directions
Al-Hatamleh, M. A. I., Hatmal, M. M., Sattar, K., Ahmad, S., Mustafa, M. Z., Bittencourt, M. D. C., & Mohamud, R. (2020) · Molecules · doi:10.3390/molecules25215017 · Cited by 120
Dysregulated transcriptional responses to SARS-CoV-2 in the periphery
McClain, M. T., Constantine, F. J., Henao, R., Liu, Y., Tsalik, E. L., Burke, T. W., Steinbrink, J. M., Petzold, E., Nicholson, B. P., Rolfe, R. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21289-y · Cited by 112
Erythroid precursors and progenitors suppress adaptive immunity and get invaded by SARS-CoV-2
Shahbaz, S., Xu, L., Osman, M. S., Sligl, W., Shields, J. A., Joyce, M., Tyrrell, D. L., Oyegbami, O., & Elahi, S. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.04.001 · Cited by 116
Nanotechnology-empowered vaccine delivery for enhancing CD8+ T cells-mediated cellular immunity
Liu, G., Zhu, M., Zhao, X., & Nie, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113889 · Cited by 114
SARS-CoV-2 Infects Human Pluripotent Stem Cell-Derived Cardiomyocytes, Impairing Electrical and Mechanical Function
Marchianò, S., Hsiang, T.-Y., Khanna, A., Higashi, T., Whitmore, L. S., Bargehr, J., Davaapil, H., Chang, J., Smith, E. A., Ong, L. P., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.02.008 · Cited by 112
A state-of-the-art review on fucoidan as an antiviral agent to combat viral infections
Pradhan, B., Nayak, R., Patra, S., Bhuyan, P. P., Behera, P. K., Mandal, A. K., Behera, C., Ki, J., Adhikary, S. P., MubarakAli, D., et al. (2022) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2022.119551 · Cited by 113
SARS-CoV-2 pandemic: An overview
Martellucci, C. A., Flacco, M. E., Cappadona, R., Bravi, F., Mantovani, L. G., & Manzoli, L. (2020) · Advances in Biological Regulation · doi:10.1016/j.jbior.2020.100736 · Cited by 116
Weathering the Cytokine Storm in COVID-19: Therapeutic Implications
Iannaccone, G., Scacciavillani, R., Buono, M. G. D., Camilli, M., Ronco, C., Lavie, C. J., Abbate, A., Crea, F., Massetti, M., & Aspromonte, N. (2020) · Cardiorenal Medicine · doi:10.1159/000509483 · Cited by 112
Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence
van Haren, F. M. P., Page, C. P., Laffey, J. G., Artigas, A., Camprubí–Rimblas, M., Nunes, Q. M., Smith, R. J., Shute, J. K., Carroll, M., Tree, J. A., et al. (2020) · Critical Care · doi:10.1186/s13054-020-03148-2 · Cited by 114
Altered amino acid profile in patients with SARS-CoV-2 infection
Rees, C. A., Rostad, C. A., Mantus, G. E., Anderson, E. J., Chahroudi, A., Jaggi, P., Wrammert, J., Ochoa, J. B., Ochoa, A. C., Basu, R. K., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2101708118 · Cited by 112
An Antioxidant Enzyme Therapeutic for COVID‐19
Qin, M., Cao, Z., Wen, J., Yu, Q., Liu, C., Wang, F., Zhang, J., Yang, F., Li, Y., Fishbein, G. A., et al. (2020) · Advanced Materials · doi:10.1002/adma.202004901 · Cited by 111
Covid‐19 and oral diseases: Crosstalk, synergy or association?
Brandini, D. A., Takamiya, A. S., Thakkar, P., Schaller, S. J., Rahat, R., & Naqvi, A. R. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2226 · Cited by 120
Acute Respiratory Distress Syndrome
Williams, G. W., Berg, N. K., Reskallah, A., Yuan, X., & Eltzschig, H. K. (2020) · Anesthesiology · doi:10.1097/aln.0000000000003571 · Cited by 123
Mitochondria: In the Cross Fire of SARS-CoV-2 and Immunity
Burtscher, J., Cappellano, G., Omori, A., Koshiba, T., & Millet, G. P. (2020) · iScience · doi:10.1016/j.isci.2020.101631 · Cited by 110
Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation: Implications for an Anti-Siglec-8 Antibody
Gebremeskel, S., Schanin, J., Coyle, K. M., Butuci, M., Luu, T. T., Brock, E. C., Xu, A., Wong, A., Leung, J., Korver, W., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.650331 · Cited by 111
Coronavirus Disease 2019–Associated Invasive Fungal Infection
Baddley, J. W., Thompson, G. R., Chen, S. C. ‐., White, P. L., Johnson, M. D., Nguyen, M. H., Schwartz, I. S., Spec, A., Ostrosky-Zeichner, L. L., Jackson, B. R., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab510 · Cited by 111
S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters
Sasaki, M., Tabata, K., Kishimoto, M., Itakura, Y., Kobayashi, H., Ariizumi, T., Uemura, K., Toba, S., Kusakabe, S., Maruyama, Y., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq4064 · Cited by 108
Haematological manifestations of COVID‐19: From cytopenia to coagulopathy
Agbuduwe, C., & Basu, S. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13491 · Cited by 112
A review on possible mechanistic insights of Nitazoxanide for repurposing in COVID-19
Lokhande, A. S., & Devarajan, P. V. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173748 · Cited by 109
Role of platelet‐to‐lymphocyte count ratio (PLR), as a prognostic indicator in COVID‐19: A systematic review and meta‐analysis
Sarkar, S., Kannan, S., Khanna, P., & Singh, A. K. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27297 · Cited by 110
SARS-CoV-2 Z-RNA activates the ZBP1-RIPK3 pathway to promote virus-induced inflammatory responses
Li, S., Zhang, Y., Guan, Z., Ye, M., Li, H., You, M., Zhou, Z., Zhang, C., Zhang, F., Lü, B., et al. (2023) · Cell Research · doi:10.1038/s41422-022-00775-y · Cited by 108
Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines
dos Santos, W. G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111272 · Cited by 108
The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19
Attiq, A., Yao, L. J., Afzal, S., & Khan, M. A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108255 · Cited by 111
IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection
Rosa, B. A., Ahmed, M., Singh, D. K., Choreño-Parra, J. A., Cole, J., Jiménez-Álvarez, L. A., Rodríguez-Reyna, T. S., Singh, B., Gonzalez, O., Carrion, R., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01829-4 · Cited by 106
Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets
Bye, A. P., Hoepel, W., Mitchell, J. L., Jegouic, S. M., Loureiro, S., Sage, T., Vidarsson, G., Nouta, J., Wuhrer, M., de Taeye, S. W., et al. (2021) · Blood · doi:10.1182/blood.2021011871 · Cited by 111
Correlation between immune response and self-reported depression during convalescence from COVID-19
Yuan, B., Li, W., Liu, H., Cai, X., Song, S., Zhao, J., Hu, X., Li, Z., Chen, Y., Zhang, K., et al. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.05.062 · Cited by 105
Possible role of HLA class-I genotype in SARS-CoV-2 infection and progression: A pilot study in a cohort of Covid-19 Spanish patients
Iturrieta-Zuazo, I., Rita, C. G., García-Soidán, A., Pintos‐Fonseca, A. D. M., Alonso-Alarcón, N., Pariente, R., Velarde, A. T., Villar, S. S., Castañer-Alabau, J. L., & Nieto-Gañán, I. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108572 · Cited by 103
COVID-19–Induced New-Onset Diabetes: Trends and Technologies
Metwally, A. A., Mehta, P., Johnson, B. S., Nagarjuna, A., & Snyder, M. P. (2021) · Diabetes · doi:10.2337/dbi21-0029 · Cited by 110
Animal models for COVID-19: advances, gaps and perspectives
Fan, C., Wu, Y., Xiong, R., Yang, Y., Ling, C., Liu, S., Liu, S., & Wang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01087-8 · Cited by 110
Association between COVID‐19 and telomere length: A bidirectional Mendelian randomization study
Huang, D., Lin, S., He, J., Wang, Q., & Zhan, Y. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28008 · Cited by 108
COVID-19 Compared to Other Pandemic Diseases
Pitlik, S. D. (2020) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10418 · Cited by 100
A public health perspective of aging: do hyper-inflammatory syndromes such as COVID-19, SARS, ARDS, cytokine storm syndrome, and post-ICU syndrome accelerate short- and long-term inflammaging?
Bektas, A., Schurman, S. H., Franceschi, C., & Ferrucci, L. (2020) · Immunity & Ageing · doi:10.1186/s12979-020-00196-8 · Cited by 102
From Anti-SARS-CoV-2 Immune Responses to COVID-19 via Molecular Mimicry
Kanduc, D. (2020) · Antibodies · doi:10.3390/antib9030033 · Cited by 104
Highly Sensitive Near-Infrared Imaging of Peroxynitrite Fluxes in Inflammation Progress
Wang, Z., Wang, W., Wang, P., Song, X., Mao, Z., & Liu, Z. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.0c05118 · Cited by 104
Role of probiotics in stimulating the immune system in viral respiratory tract infections: A narrative review
Lehtoranta, L., Latvala, S., & Lehtinen, M. J. (2020) · Nutrients · doi:10.3390/nu12103163 · Cited by 103
Clearance and persistence of SARS‐CoV‐2 RNA in patients with COVID‐19
do Carmo, A., Pereira‐Vaz, J., Mota, V., Mendes, A., Morais, C., da Silva, A. C., Camilo, E., Pinto, C. S., Cunha, E., Pereira, J., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26103 · Cited by 103
The direct evidence and mechanism of traditional Chinese medicine treatment of COVID-19
An, X., Zhang, Y., Duan, L., Jin, D., Zhao, S., Zhou, R., Duan, Y., Lian, F., & Tong, X. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111267 · Cited by 101
SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity
Trinité, B., Tarrés-Freixas, F., Rodon, J., Pradenas, E., Urrea, V., Marfil, S., de la Concepción, M. L. R., Ávila‐Nieto, C., Aguilar‐Gurrieri, C., Barajas, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-81862-9 · Cited by 104
Non‐steroidal anti‐inflammatory drugs, prostaglandins, and COVID‐19
Robb, C. T., Goepp, M., Rossi, A. G., & Yao, C. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15206 · Cited by 104
The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment
van Vuren, E. J., Steyn, S. F., Brink, C. B., Möller, M., Viljoen, F. P., & Harvey, B. H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111200 · Cited by 106
“include CD4 + T cells, CD14+, CD16+, inflammatory monocytes, IL-2, IL-7, IL-10, granulocyte colony- stimulating factor (G-CSF), IP-10, MCP-1, macrophage inflammatory protein 1α (MIP-1α), TNF and S protein: V483A, L455I, F456 V and G476S [356].”
Cellular senescence as a potential mediator of COVID‐19 severity in the elderly
Nehme, J., Borghesan, M., Mackedenski, S., Bird, T. G., & Demaria, M. (2020) · Aging Cell · doi:10.1111/acel.13237 · Cited by 94
Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature
Hensel, A., Bauer, R., Heinrich, M., Spiegler, V., Kayser, O., Hempel, G., & Kraft, K. (2020) · Planta Medica · doi:10.1055/a-1177-4396 · Cited by 101
Prioritized Research for the Prevention, Treatment, and Reversal of Chronic Disease: Recommendations From the Lifestyle Medicine Research Summit
Yoram Vodovotz, B., Barnard, N. D., Hu, F. B., Jakicic, J. M., Lianov, L. S., Loveland, D., Buysse, D. J., Szigethy, E., Finkel, T., Sowa, G., et al. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.585744 · Cited by 116
Calming the Storm: Natural Immunosuppressants as Adjuvants to Target the Cytokine Storm in COVID-19
Peter, A. E., Sandeep, B. V., Rao, B. G., & Kalpana, V. L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.583777 · Cited by 106
“Mask up to keep it up”: Preliminary evidence of the association between erectile dysfunction and COVID‐19
Sansone, A., Mollaioli, D., Ciocca, G., Colonnello, E., Limoncin, E., Balercia, G., & Jannini, E. A. (2021) · Andrology · doi:10.1111/andr.13003 · Cited by 103
Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2–Specific IgG
Schwarzkopf, S., Krawczyk, A., Knop, D., Klump, H., Heinold, A., Heinemann, F., Thümmler, L., Temme, C., Breyer, M., Witzke, O., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2701.203772 · Cited by 141
Determinants of persistent post-COVID-19 symptoms: value of a novel COVID-19 symptom score
Galal, I., Hussein, A. A. R. M., Amin, M. T., Saad, M. M., Zayan, H. E. E., Abdelsayed, M. Z., Moustafa, M. M., Ezzat, A. R., Helmy, R. E., Abd-Elaal, H., et al. (2021) · Egyptian Journal of Bronchology · doi:10.1186/s43168-020-00049-4 · Cited by 110
Pan-Echinocandin-Resistant Candida glabrata Bloodstream Infection Complicating COVID-19: A Fatal Case Report
Posteraro, B., Torelli, R., Vella, A., Leone, P. M., Angelis, G. D., Carolis, E. D., Ventura, G., Sanguinetti, M., & Fantoni, M. (2020) · Journal of Fungi · doi:10.3390/jof6030163 · Cited by 100
Serum S100B protein as a marker of severity in Covid-19 patients
Aceti, A., Margarucci, L. M., Scaramucci, E., Orsini, M., Salerno, G., Sante, G. D., Gianfranceschi, G., Liddo, R. D., Valeriani, F., Ria, F., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-75618-0 · Cited by 98
Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model
Proud, P. C., Tsitoura, D. C., Watson, R. J., Chua, B. Y. L., Aram, M. J., Bewley, K. R., Cavell, B. E., Cobb, R., Dowall, S., Fotheringham, S. A., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103153 · Cited by 98
Targeting ACE2 for COVID-19 Therapy: Opportunities and Challenges
Jia, H., Neptune, E., & Cui, H. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0322ps · Cited by 100
Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence
Lin, H., Cho, S., Aravamudan, V. M., Sanda, H., Palraj, R., Molton, J. S., & Venkatachalam, I. (2021) · Infection · doi:10.1007/s15010-020-01557-7 · Cited by 101
SARS-CoV-2 productively infects human brain microvascular endothelial cells
Yang, R., Huang, K. L., Xu, B., Li, L., Zhang, Y., Tan, C., Kim, K. S., 陈焕春, Jin, M., & Wang, X. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02514-x · Cited by 101
Thromboembolic events and Covid-19
Ribes, A. M., Bounes, F. V., Mémier, V., Poette, M., Au-Duong, J., Garcia, C., Minville, V., Siè, P., Bura-Rivière, A., Voisin, S., et al. (2020) · Advances in Biological Regulation · doi:10.1016/j.jbior.2020.100735 · Cited by 97
Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines
Flanagan, K. L., Best, E., Crawford, N. W., Giles, M., Koirala, A., Macartney, K. K., Russell, F. M., Teh, B. W., & Wen, S. C.-H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.579250 · Cited by 96
Mechanistic Modeling of SARS‐CoV‐2 and Other Infectious Diseases and the Effects of Therapeutics
Perelson, A. S., & Ke, R. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2160 · Cited by 95
Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19)
de Alencar, J. C. G., Moreira, C. D. L., Veiga, A. D. M., Chaves, C. E., Fukuhara, M. A., da Silva, E. A., Miyamoto, M. D. F. S., Pinto, V. B., Bueno, C. G., Neto, F. L., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1443 · Cited by 98
Gold-Nanostar-Chitosan-Mediated Delivery of SARS-CoV‑2 DNA Vaccine for Respiratory Mucosal Immunization: Development and Proof-of-Principle
Sukumar, U. K., Afjei, R., Ferrara, K. W., Massoud, T. F., & Paulmurugan, R. (2021) · ACS Nano · doi:10.1021/acsnano.1c05002 · Cited by 95
The short isoform of the host antiviral protein ZAP acts as an inhibitor of SARS-CoV-2 programmed ribosomal frameshifting
Zimmer, M. M., Kibe, A., Rand, U., Pekárek, L., Ye, L., Buck, S., Smyth, R. P., Čičin‐Šain, L., & Caliskan, N. (2021) · Nature Communications · doi:10.1038/s41467-021-27431-0 · Cited by 99
Application of mobile health to support the elderly during the COVID-19 outbreak: A systematic review
Abbaspur-Behbahani, S., Monaghesh, E., Hajizadeh, A., & Fehresti, S. (2022) · Health Policy and Technology · doi:10.1016/j.hlpt.2022.100595 · Cited by 95
Re-analysis of Single Cell Transcriptome Reveals That the NR3C1-CXCL8-Neutrophil Axis Determines the Severity of COVID-19
Park, J. H., & Lee, H. K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02145 · Cited by 93
Targeting Lipid Rafts as a Strategy Against Coronavirus
Sorice, M., Misasi, R., Riitano, G., Manganelli, V., Martellucci, S., Longo, A., Garofalo, T., & Mattei, V. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.618296 · Cited by 94
SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation
Xu, G., Li, Y., Zhang, S., Peng, H., Wang, Y., Li, D., Jin, T., He, Z., Tong, Y., Qi, C., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00578-7 · Cited by 95
Upregulated type I interferon responses in asymptomatic COVID-19 infection are associated with improved clinical outcome
Masood, K. I., Yameen, M., Ashraf, J., Shahid, S., Mahmood, S. F., Nasir, A., Nasir, N., Jamil, B., Ghanchi, N. K., Khanum, I., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-02489-4 · Cited by 94
Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies
Chung, Y.-S., Lam, C.-Y., Tan, P.-H., Tsang, H. F., & Wong, S. C. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158155 · Cited by 120
Immunobiology and immunotherapy of COVID‐19: A clinically updated overview
Esmaeilzadeh, A., & Elahi, R. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30076 · Cited by 94
Coronavirus disease 2019 and cardiovascular complications: focused clinical review
Saeed, S., Tadić, M., Larsen, T. H., Grassi, G. M., & Mancia, G. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002819 · Cited by 93
Increased Serum Levels of Soluble TNF-α Receptor Is Associated With ICU Mortality in COVID-19 Patients
Mortaz, E., Tabarsi, P., Jamaati, H., Roofchayee, N. D., Dezfuli, N. K., Hashemian, S. M. R., Moniri, A., Marjani, M., Malekmohammad, M., Mansouri, D., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.592727 · Cited by 93
Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial
Zarrabi, M., Shahrbaf, M. A., Nouri, M., Shekari, F., Hosseini, S.-E., Hashemian, S. M. R., Aliannejad, R., Jamaati, H., Khavandgar, N., Alemi, H., et al. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03402-8 · Cited by 93
The Roborovski Dwarf Hamster Is A Highly Susceptible Model for a Rapid and Fatal Course of SARS-CoV-2 Infection
Trimpert, J., Vladimirova, D., Dietert, K., Abdelgawad, A., Kunec, D., Dökel, S., Voß, A., Gruber, A. D., Bertzbach, L. D., & Osterrieder, N. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108488 · Cited by 89
Macrophage biomimetic nanocarriers for anti-inflammation and targeted antiviral treatment in COVID-19
Tan, Q., He, L., Meng, X., Wang, W., Pan, H., Yin, W., Zhu, T., Huang, X., & Shan, H. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00926-0 · Cited by 93
The Effects of COVID-19 on the Placenta During Pregnancy
Sadeghirad, H., Röhl, J., Stylianou, N., Allenby, M. C., Bazaz, S. R., Warkiani, M. E., Souza-Fonseca-Guimarães, F., Clifton, V. L., & Kulasinghe, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.743022 · Cited by 94
Changes in breast cancer management during the Corona Virus Disease 19 pandemic: An international survey of the European Breast Cancer Research Association of Surgical Trialists (EUBREAST)
Gasparri, M. L., Gentilini, O., Lüftner, D., Kuehn, T., Kaidar‐Person, O., & Poortmans, P. M. (2020) · The Breast · doi:10.1016/j.breast.2020.05.006 · Cited by 90
Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: a case series
Weber, A. G., Chau, A. S., Egeblad, M., Barnes, B. J., & Janowitz, T. (2020) · Molecular Medicine · doi:10.1186/s10020-020-00215-w · Cited by 91
The up‐to‐date pathophysiology of Kawasaki disease
Hara, T., Yamamura, K., & Sakai, Y. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1284 · Cited by 92
Association of vitamin D status with COVID-19 and its severity
Bae, J. H., Choe, H. J., Holick, M. F., & Lim, S. K. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09705-6 · Cited by 94
Identification of Parameters Representative of Immune Dysfunction in Patients with Severe and Fatal COVID-19 Infection: a Systematic Review and Meta-analysis
Qin, R., He, L., Yang, Z., Jia, N., Chen, R., Xie, J., Fu, W., Chen, H., Lin, X., Huang, R., et al. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08908-8 · Cited by 97
Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortalityPreprint
Silva, J. D. S., Lucas, C. G. D. O., Sundaram, M. E., Israelow, B., Wong, P., Klein, J., Tokuyama, M., Lu, P., Venkataraman, A., Liu, F., et al. (2021) · medRxiv · doi:10.1101/2021.01.04.21249236 · Cited by 90
Reduced Monocytic Human Leukocyte Antigen-DR Expression Indicates Immunosuppression in Critically Ill COVID-19 Patients
Spinetti, T., Hirzel, C., Fux, M., Walti, L. N., Schober, P. R., Stueber, F., Luedi, M. M., & Schefold, J. C. (2020) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000005044 · Cited by 90
A Granulocytic Signature Identifies COVID-19 and Its Severity
Vitte, J., Diallo, A. B., Boumaza, A. F., Lopez, A., Michel, M., Allardet-Servent, J., Mezouar, S., Sérémé, Y., Busnel, J., Miloud, T., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa591 · Cited by 90
Retracted: Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection
Hill, A. M., Abdulamir, A., Ahmed, S., Asghar, A., Babalola, O. E., Basri, R., Chaccour, C., Chachar, A. Z. K., Chowdhury, A. T. M., Elgazzar, A., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab358 · Cited by 98
Retracted
Cancer as a prospective sequela of long COVID‐19
Saini, G., & Aneja, R. (2021) · BioEssays · doi:10.1002/bies.202000331 · Cited by 93
“Excessive proinflammatory cytokine release (cytokine storm) and multi-organ coagulation abnormalities are hallmarks of severe COVID-19 and can inflict extensive tissue damage.[11] However, the time required for immune homeostasis restoration after virus elimination, as well as the underlying mechanisms, remain unknown.”
A high-resolution temporal atlas of the SARS-CoV-2 translatome and transcriptome
Kim, D., Kim, S., Park, J., Chang, H. R., Chang, J., Ahn, J., Park, H., Park, J., Son, N., Kang, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25361-5 · Cited by 88
Inflammation at the crossroads of COVID-19, cognitive deficits and depression
Silva, N. M. L. E., Barros‐Aragão, F. G. Q., Felice, F. G. D., & Ferreira, S. T. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109023 · Cited by 96

Authors: Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P.
Affiliations: Agency for Science, Technology and Research (SG)
National University of Singapore (SG)
Corresponding author: Rénia, Laurent
MacAry, Paul A.
Ng, Lisa F. P.
ORCID: Tay, Matthew Zirui
Poh, Chek Meng
Rénia, Laurent
MacAry, Paul A.
Ng, Lisa F. P.
Venue: Nature Reviews Immunology
Publisher: Springer Science and Business Media LLC
Published: 2020-04-28
Volume: 20
Issue: 6
Pages: 363-374
ISSN: 1474-1733 (ISSN-L)
1474-1741
DOI: 10.1038/s41577-020-0311-8
PMC: PMC7187672
OpenAlex: W3018517500
Cited by: 4,360
References: 136
Citations by year: 2026: 82 · 2025: 169 · 2024: 320 · 2023: 552 · 2022: 899 · 2021: 1369 · 2020: 961
FWCI: 44.76
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature reviews. Immunology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
National University of Singapore (submittedVersion)
Funders: Medical Research Council
Biomedical Research Council
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
Keywords: SARS-CoV-2, COVID-19 pandemic, immune response, inflammation, pathophysiology, immune dysregulation, SARS-CoV, MERS-CoV, lower respiratory tract infection, immune regulation, antiviral therapy, therapeutic interventions
MeSH terms: Betacoronavirus, COVID-19, SARS-CoV-2, Animals, Humans, Inflammation, Pneumonia, Viral, Coronavirus Infections, Disease Progression, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The trinity of COVID-19: immunity, inflammation and intervention

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks